Involvement of haptoglobin in prevention of oxidative stress cause by hemoglobin in preeclampsia


Haptoglobin (Hp) is a hemoglobin (Hb) binding protein which plays an important role in neutralizing oxidation reactions stimulated by heme-derived iron. Differences in Hp types due to the polymorphic nature of the gene have led to the discovery that individuals carrying the Hp 2-2 genotype are at increased risk of developing vascular complications in the setting of diabetes. Preeclampsia is a pregnancy related disease that is thought to be caused by increases in oxidative stress. The role of Hp polymorphism is determining preeclampsia has been addressed by several clinical studies but the results have been contradictory. Larger longitudinal studies are needed to answer this important question.

Share and Cite:

Goldenstein, H. , Levy, N. and Levy, A. (2012) Involvement of haptoglobin in prevention of oxidative stress cause by hemoglobin in preeclampsia. Advances in Bioscience and Biotechnology, 3, 1037-1042. doi: 10.4236/abb.2012.327126.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Uzan, J., Carbonnel, M., Piconne, O., Asmar, R. and Ayoubi, J.M. (2011) Pre-eclampsia: Pathophysiology, diagnosis, and management. Journal of Vascular Health and Risk Management, 7, 467-474.
[2] Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E., Epstein, F.H., Sukhatme, V.P. and Karumanchi, S.A. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. The Journal of Clinical Investigation, 111, 649-658.
[3] Siddiqui, I.A., Jaleel, A., Tamimi, W. and Al Kadri, H.M. (2010) Role of oxidative stress in the pathogenesis of preeclampsia. Archives of Gynecology and Obstetrics, 282, 469-474. doi:10.1007/s00404-010-1538-6
[4] Levy, A.P., Asleh, R., Blum, S., Levy, N.S., Miller-Lotan, R., Kalet-Litman, S., Anbinder, Y., Lache, O., Nakhoul, F.M., Asaf, R., Farbstein, D., Pollak, M., Soloveichik, Y.Z., Strauss, M., Alshiek, J., Livshits, A., Schwartz, A., Awad, H., Jad, K. and Goldenstein, H. (2010) Haptoglobin: Basic and clinical aspects. Antioxidants & Redox Signaling, 12, 293-304. doi:10.1089/ars.2009.2793
[5] Langlois, M.R. and Delanghe, J.R. (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry, 42, 1589-1600.
[6] Berkova, N., Lemay, A., Dresser, D.W., Fontaine, J.Y., Kerizit, J. and Goupil, S. (2001) Haptoglobin is present in human endometrium and shows elevated levels in the decidua during pregnancy. Molecular Human Reproduction, 7, 747-754. doi:10.1093/molehr/7.8.747
[7] Buehler, P.W., Abraham, B., Vallelian, F., Linnemayr, C., Pereira, C.P., Cipollo, J.F., Jia, Y., Mikolajczyk, M., Boretti, F.S., Schoedon, G., Alayash, A.I. and Schaer, D.J. (2009) Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood, 113, 2578-2586. doi:10.1182/blood-2008-08-174466
[8] Asleh, R., Marsh, S., Shilkrut, M., Binah, O., Guetta, J., Lejbkowicz, F., Enav, B., Shehadeh, N., Kanter, Y., Lache, O., Cohen, O., Levy, N.S. and Levy, A.P. (2003) Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circulation Research, 92, 1193-1200. doi:10.1161/01.RES.0000076889.23082.F1
[9] Levy, A.P., Hochberg, I., Jablonski, K., Resnick, H.E., Lee, E.T., Best, L. and Howard, B.V. (2002) Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The strong heart study. Journal of the American College of Cardiology, 40, 1984-1990. doi:10.1016/S0735-1097(02)02534-2
[10] Costacou, T., Ferrell, R.E. and Orchard, T.J. (2008) Haptoglobin genotype: A determinant of cardiovascular complication risk in type 1 diabetes. Diabetes, 57, 1702-1706. doi:10.2337/db08-0095
[11] Roguin, A., Koch, W., Kastrati, A., Aronson, D., Schomig, A. and Levy, A.P. (2003) Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care, 26, 2628-2631. doi:10.2337/diacare.26.9.2628
[12] Suleiman, M., Aronson, D., Asleh, R., Kapeliovich, M.R., Roguin, A., Meisel, S.R., Shochat, M., Sulieman, A., Reisner, S.A., Markiewicz, W., Hammerman, H., Lotan, R., Levy, N.S. and Levy, A.P. (2005) Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes, 54, 2802-2806. doi:10.2337/diabetes.54.9.2802
[13] Milman, U., Blum, S., Shapira, C., Aronson, D., Miller-Lotan, R., Anbinder, Y., Alshiek, J., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A. and Levy, A.P. (2008) Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective double-blinded clinical trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 341-347. doi:10.1161/ATVBAHA.107.153965
[14] Costacou, T., Ferrell, R.E., Ellis, D. and Orchard, T.J. (2009) Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes, 8, 2904-2909. doi:10.2337/db09-0874
[15] Levy, A.P., Roguin, A., Hochberg, I., Herer, P., Marsh, S., Nakhoul, F.M. and Skorecki, K. (2000) Haptoglobin phenotype and vascular complications in patients with diabetes. The New England Journal of Medicine, 343, 969-970. doi:10.1056/NEJM200009283431313
[16] Nakhoul, F.M., Zoabi, R., Kanter, Y., Zoabi, M., Skorecki, K., Hochberg, I., Leibu, R., Miller, B. and Levy, A.P. (2001) Haptoglobin phenotype and diabetic nephropathy. Diabetologia, 44, 602-604. doi:10.1007/s001250051666
[17] Mustafa, S., Vukovich, T., Prikoszovich, T., Winzer, C., Schneider, B., Esterbauer, H., Wagner, O. and Kautzky-Willer, A. (2004) Haptoglobin phenotype and gestational diabetes. Diabetes Care, 27, 2103-2107. doi:10.2337/diacare.27.9.2103
[18] Wobeto, V.P., Pinho Pda, C., Souza, J.R., Zaccariotto, T.R. and Zonati Mde, F. (2011) Haptoglobin genotypes and refractory hypertension in type 2 diabetes mellitus patients. Arquivos Brasileiros de Cardiologia, 97, 338-345. doi:10.1590/S0066-782X2011005000107
[19] Delanghe, J.R., Duprez, D.A., De Buyzere, M.L., Bergez, B.M., Claeys, L.R., Leroux-Roels, G.G. and Clement, D.L. (1995) Refractory hypertension is associated with the haptoglobin 2-2 phenotype. Journal of Cardiovascular Risk, 2, 131-136. doi:10.1097/00043798-199504000-00008
[20] Miranda-Vilela, A.L., Akimoto, A.K., Alves, P.C., Ferreira, L.B., Lordelo, G.S., Melo, J.G., Grisolia, C.K., Oliveira, S.F. and Klautau-Guimaraes, M.N. (2010) Evidence for an association between haptoglobin and MnSOD (Val9Ala) gene polymorphisms in essential hypertension based on a Brazilian case-control study. Genetics and Molecular Research, 9, 2166-2175. doi:10.4238/vol9-4gmr973
[21] Sammour, R.N., Nakhoul, F.M., Levy, A.P., Miller-Lotan, R., Nakhoul, N., Awad, H.R., Gonen, R. and Ohel, G. (2010) Haptoglobin phenotype in women with preeclampsia. Endocrine, 38, 303-308. doi:10.1007/s12020-010-9392-7
[22] Depypere, H.T., Langlois, M.R., Delanghe, J.R., Temmerman, M. and Dhont, M. (2006) Haptoglobin polymorphism in patients with preeclampsia. Clinical Chemistry and Laboratory Medicine, 44, 924-928. doi:10.1515/CCLM.2006.182
[23] Raijmakers, M.T., Roes, E.M., Te Morsche, R.H., Steegers, E.A. and Peters, W.H. (2003) Haptoglobin and its association with the HELLP syndrome. Journal of Medical Genetics, 40, 214-216. doi:10.1136/jmg.40.3.214
[24] Bottini, N., Gimelfarb, A., Gloria-Bottini, F., La Torre, M., Lucarelli, P. and Lucarini, N. (1999) Haptoglobin genotype and natural fertility in humans. Fertility and Sterility, 72, 293-296. doi:10.1016/S0015-0282(99)00210-1
[25] Chappell, L.C., Seed, P.T., Briley, A.L., Kelly, F.J., Lee, R., Hunt, B.J., Parmar, K., Bewley, S.J., Shennan, A.H., Steer, P.J.and Poston, L. (1999) Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial. Lancet, 354, 810-816.
[26] Beazley, D., Ahokas, R., Livingston, J., Griggs, M. and Sibai, B.M. (2005) Vitamin C and E supplementation in women at high risk for preeclampsia: A double-blind, placebo-controlled trial. American Journal of Obstetrics & Gynecology, 192, 520-521. doi:10.1016/j.ajog.2004.09.005
[27] Rossi, A.C. and Mullin, P.M. (2011) Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: A systematic review with meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 158, 9-16. doi:10.1016/j.ejogrb.2011.04.010
[28] Miller, E.R. 3rd, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J. and Guallar, E. (2005) Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine, 142, 37- 46.
[29] Levy, A.P., Levy, J.E., Kalet-Litman, S., Miller-Lotan, R., Levy, N.S., Asaf, R., Guetta, J., Yang, C., Purushothaman, K.R., Fuster, V. and Moreno, P.R. (2007) Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 134-140. doi:10.1161/01.ATV.0000251020.24399.a2

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.